UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,979,539 B2
APPLICATION NO. : 09/897844
DATED : December 27, 2005
INVENTOR(S) : George Norbert Cox, III et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Office initiated Certificate of Correction Memo

The following claims are corrected as follows (formatted by strikethrough of deleted text and underlining added text)

In column 73 lines 29-42 should read as follows:

1. A method of inhibiting expression of an endogenous cellular ~~pine~~ gene in a cell, the method comprising the step of:

administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first engineered zinc finger protein, wherein

(i) said polynucleotide sequence is operably linked to a promoter,

(ii) the nucleic acid molecule expresses the zinc finger protein ~~is less~~ in the cell;

(iii) the zinc finger protein contacts a first target site in the endogenous cellular gene; and

(iv) the K.sub.d of the zinc finger protein is less than about 25 nM;

thereby inhibiting expression of the endogenous cellular gene.

In column 73 lines 43-49 should read as follows:

2. The method of claim 1 wherein the step of administering further comprises administering a second zinc finger protein-encoding nucleic acid operably linked to a promoter that expresses a second zinc finger protein in the cell, and wherein the ~~stop~~ step of contacting ~~father~~ further comprises contacting a second target site in the endogenous cellular gene with the second zinc finger protein.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,979,539 B2
APPLICATION NO. : 09/897844
DATED : December 27, 2005
INVENTOR(S) : George Norbert Cox, III et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 73 lines 50-51 should read as follows:

3. The method claim 2, wherein the ~~flat wad~~ first and second target sites are adjacent.

Column 73 lines 52-54 should read as follows:

4. The method ~~of~~ of claim 3, wherein the first and second zinc finger proteins are covalently linked, ~~miming~~ forming a fusion protein.

Column 74 lines 42-45 should read as follows:

16. The method of claim 1, wherein the step of administering the nucleic acid molecule to the cell comprises administering the nucleic acid molecule in a lipid:nucleic acid complex or as naked nucleic acid.

Column 74 lines 49-50 should read as follows:

18. The method of claim ~~1~~ 17, wherein the expression vector is a viral expression vector.

Column 74 lines 51-53 should read as follows:

19. The method of claim 18, wherein the expression vector is a retroviral expression vector, an ~~aderoviral~~ adenoviral expression vector, or an AAV expression vector.

Column 74 lines 54-56 should read as follows:

20. The method of claim 18 wherein the promoter to which the zinc finger-encoding nucleic acid is operably linked is an ~~inducable~~ inducible promoter.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,979,539 B2
APPLICATION NO. : 09/897844
DATED : December 27, 2005
INVENTOR(S) : George Norbert Cox, III et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 75 lines 13-29 should read as follows:

29. A method of inhibiting expression of an endogenous cellular ~~pine~~ gene in a cell, the method comprising the step of: administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first engineered zinc finger protein, wherein

(i) said polynucleotide sequence is operably linked to a promoter;

(ii) the nucleic acid molecule expresses the zinc finger protein in the cell;

(iii) the fusion zinc finger protein comprises six fingers and a regulatory domain;

(iv) the fusion zinc finger protein contacts a target site in the endogenous cellular gene and;

(v) the K_d of the zinc finger protein is less than about 25 nM;

thereby inhibiting expression of the endogenous cellular gene.

Column 75 lines 45-51 should read as follows:

31. The method of claim 30, wherein the step of administering ~~father~~ further comprises administering a second zinc finger protein-encoding nucleic add operably linked to a promoter that expresses a second zinc finger protein in the cell and wherein the step of contacting further comprises contacting a second target site ~~ix~~ in the endogenous cellular gene with the second zinc finger protein.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,979,539 B2
APPLICATION NO. : 09/897844
DATED : December 27, 2005
INVENTOR(S) : George Norbert Cox, III et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 76 lines 18-21 should read as follows:

45. The method of claim 30, wherein the step of administering the nucleic acid molecule to the cell comprises administering the nucleic acid molecule in a lipid:nucleic acid complex or as ~~marked~~ naked nucleic acid.

Column 76 lines 22-24 should read as follows:

46. The method of claim 30, wherein the nucleic acid molecule is an expression vector comprising a zinc finger protein encoding nucleic acid operably linked toe a promoter.

Column 76 lines 30-32 should read as follows:

49. The method of claim 47, wherein the promoter to which the zinc finger ~~protein~~ encoding ~~by a~~ nucleic acid is operably linked to an inducible promoter.

Column 76 lines 33-35 should read as follows:

50. The method of claim 47, wherein the promoter to which the zinc finger ~~protein~~ encoding ~~by a~~ nucleic acid is operably linked is a weak promoter.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,979,539 B2
APPLICATION NO. : 09/897844
DATED : December 27, 2005
INVENTOR(S) : George Norbert Cox, III et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 76 lines 44-47 should read as follows:

54. The method of claim ~~31~~ 30, wherein the target site is adjacent to an RNA polymerase pause site, wherein the RNA polymerase pause site is downstream of a transcription initiation site of the endogenous cellular gene.

This certificate supersedes the Certificate of Correction issued April 22, 2008.

Signed and Sealed this

Twenty-seventh Day of May, 2008

JON W. DUDAS
Director of the United States Patent and Trademark Office